Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Living With Narcolepsy: Symptoms and Misconceptions

YourUpdateTV

Confusion, stereotypes, and stigma about the sleep disorder narcolepsy persist to this day. This can lead to a long time to diagnosis and prevent people who think they have narcolepsy from reaching out to a healthcare professional to learn more. So, what is narcolepsy? Narcolepsy is a rare, chronic, debilitating neurological disorder that affects the way the brain controls sleep-wake cycles. 1,2 Narcolepsy affects approximately 165,000 Americans, with one of its main symptoms being excessive daytime sleepiness, or the inability to stay awake and alert during the day. 1 Other symptoms may include cataplexy, which is the sudden and brief loss of muscle strength or tone brought on by certain emotions or situations, sleep paralysis, vivid hallucinations when falling asleep or waking up, and disturbed nighttime sleep. 3,4 Narcolepsy is estimated to be severely underdiagnosed. 5,6 It can take an average of 10 years for people living with narcolepsy to be diagnosed after experiencing their first symptoms. 5 Narcolepsy can disrupt everyday life, 1 but the symptoms of narcolepsy aren’t always obvious, and may be inaccurately attributed to other medical conditions. 3,7 Getting to know narcolepsy means recognizing the symptoms, understanding their impact, and finding resources and support to help manage the disorder. Dr. Michael J. Thorpy, a world-renowned sleep specialist and narcolepsy expert based in New York, New York, and Jessica, a person living with narcolepsy, conducted a nationwide media tour in conjunction with Your Update TV and Harmony Biosciences to help address misconceptions, learn more about the signs and symptoms, find out what it is like to live with narcolepsy, and discover resources to help those impacted. For more information visit: WWW.KNOWNARCOLEPSY.COM and WWW.KNOWNARCOLEPSY.COM/STORIES References: 1 National Institutes of Health. Narcolepsy. U.S. Department of Health and Human Services. May 2017. 2 Narcolepsy Fact Sheet. NIH Publication No. 17-1637. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Narcolepsy-Fact-Sheet. 3 American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed.; 2014. 4 Silber MH, Krahn LE, Olson EJ, Pankratz VS. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep. 2002;25(2):197-202. 5 Overeem, Sebastiaan & Reading, Paul & Bassetti, Claudio. (2012). Narcolepsy. Sleep Medicine Clinics. 7. 263–281. 10.1016/j.jsmc.2012.03.013. 6 Carter LP, Acebo C, Kim A. Patients' journeys to a narcolepsy diagnosis: a physician survey and retrospective chart review. Postgrad Med. 2014;126(3):216-224. 7 Thorpy M, Morse AM. Reducing the clinical and socioeconomic burden of narcolepsy by earlier diagnosis and effective treatment. Sleep Med Clin. 2017;12(1):61-71. About YourUpdateTV: YourUpdateTV i s a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

October 15, 2021 03:00 PM Eastern Daylight Time

Video

Media OutReach Newswire Partners with The International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) to Promote Mental Health in Children and Adolescents

Media Outreach

HONG KONG SAR - Media OutReach - 13 October 2021 - Media OutReach, the first global newswire and press release distribution service provider founded in Asia, is pleased to announce a global partnership with The International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP), an international non-profit organization established in 1937. IACAPAP's mission is to advocate for the promotion of the mental health and development of children and adolescents through policy, practice, and research. Under this partnership, Media OutReach Newswire will fully support IACAPAP's global communications goals by exclusively distributing their market-specific press releases through Asia Pacific, USA, UK, Europe, Middle East, Africa and Latin America. IACAPAP has numerous activities aimed to promote child and adolescent mental health around the globe. Among these are the bi-annual world congresses where scientific advancements are shared. The IACAPAP also educates mental health professionals through a free e-textbook, online and in-person courses, and an open access scientific journal. Career development programs for early career professionals through the flagship Donald Cohen programme and Helmut Remschmidt Research Seminars are also carried out. "We are very pleased to engage Media OutReach to be our global newswire partner to help us promote youth mental health issues around the world. By leveraging their expertise in media industry and global distribution network, we hope our message will reach a global audience. In a world where one out of 5 children suffer from a mental health problem that is often not addressed, spreading knowledge and helping to combat stigma is invaluable." Said Prof. Daniel Fung, the IACAPAP President. "As the global newswire partner to IACAPAP, Media OutReach Newswire plays an integral role in helping the organisation to spread awareness about the importance of prevention, promotion, and intervention of mental health issues in children and young people around the world. We hope by becoming the voice of the organisation, the society will come to the realisation that mental health issues in children and young people should not be stigmatized and that there are effective interventions for youth with mental health problems. Furthermore, IACAPAP's website has useful resources on topics related to children and young people's mental health issues that anyone, including parents, children, young people, or even members of the media, can access for free. We will also be distributing thought leadership articles from the IACAPAP every quarter on pertinent public youth mental health issues. We hope through knowledge sharing and imparting positive messages, we can collectively make a positive difference in people's lives. Knowledge changes perception and shape's opinion." Said Ms. Jennifer Kok, the Founder & CEO of Media OutReach." Media OutReach has been supporting numerous local and international non-profit organisations which focus on social and mental wellbeing of children and young people. "We help on the premise that every child matter, regardless where they live and what skin colour they are, no child or adolescent should be neglected. They are the future of the world, and this our vision aligns with that of IACAPAP's. We are very certain that this partnership will bring a positive impact to the society and help to change people's attitudes towards mental health issue. More importantly, we want parents and society to regard seeking mental health advice as just the same as going to your general practitioners." She continued. Media OutReach's guarantee online news posting helps to make articles available to a global audience and by delivering news directly to the inboxes of relevant journalists out of 140,000 media contacts, the newswire will ensure IACAPAP's news is readily available for journalists who would like to write or research about related topics. "With Media OutReach's global press release distribution capabilities, we are able to make changes impactfully." Said Ms Kok. About IACAPAP The International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) dates its origin back to 1937 in Paris, France. Initially named the International Committee of Child Psychiatrists, it was renamed IACPAP in 1948 incorporating allied professions, and in 1978 adolescent psychiatry was added to form IACAPAP. IACAPAP's mission is to advocate for the promotion of the mental health and development of children and adolescents through policy, practice and research. About Media OutReach Founded in 2009, and with its headquarters in Hong Kong, Media OutReach is the first global newswire founded in Asia Pacific with offices in Singapore, Malaysia, Vietnam, Japan, China and Taiwan. Media OutReach is the only newswire that owns its distribution network across 24 countries across Asia Pacific; possessing a database of more than 140,000 journalists, 400 trade categories, 65,000 media titles and 480 media partnerships, it is revolutionising the industry by providing guarantee online news posting by language for each distribution. With proprietary technology at its core, Media OutReach Newswire distributes multi-language and multimedia press release contents directly to the inboxes of targeted editors and journalists to optimize news write-ups, build media relations and automates the reporting process with key performance metrics and its pioneering post-release reports gives insights into journalists accessing the release by publication and by country. Media OutReach Newswire is the go-to news release and content distribution partner for public relations, social marketing, digital agencies, and organizations in Asia Pacific. For more information on Media OutReach, please visit www.media-outreach.com Contact Details IACAPAP Ms Sue Wong, Administrator suewong.iacapap@gmail.com Media OutReach Ms. Jowie Wong, Director of Marketing Communications Jowie.wong@media-outreach.com Company Website https://www.xxx.com/

October 15, 2021 06:33 AM Eastern Daylight Time

MCR Labs Announces First Annual “Cannabis Science Fair,” Begins Accepting Submissions

MCR Labs

Massachusetts-based cannabis testing company MCR Labs will host its inaugural “Cannabis Science Fair” at The BUild Lab IDG Capital Student Innovation Center on December 11. MCR Labs is partnering with The Cannabis Center of Excellence (CCoE) and Innovate@BU to organize the event, which is billed as “an exhibition of research and progress from the institutions working to expand our cannabis knowledge.” Groups interested in showcasing their cannabis-focused work at the science fair are invited to submit abstracts and other materials to MCR Labs via https://ma.mcrlabs.com/event/the-cannabis-science-fair. “We’re extremely excited about the potential for this event,” said Melissa Kenton, MCR Labs event and outreach coordinator. “It’s been on our radar for over a year, and we cannot wait to see what our fellow cannabis scientists and innovators are ready to share with us and the community.” Submissions for the Cannabis Science Fair will be assessed by MCR Labs and their event partners and selected for inclusion based on the soundness of methodologies, their potential scientific or industry impact and how thoroughly their findings are presented. A limited number of submissions will be selected for full presentations, poster presentations and demonstrations of any devices or prototypes. Projects chosen to be exhibited at the Cannabis Science Fair and other details about the event will be announced in November. Sponsorship opportunities are available and the event will be free to the public. Please contact MCR Labs for additional information about the event and how to join. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Joe Crinkley +1 857-230-0839 joe@mcrlabs.com Company Website http://mcrlabs.com

October 14, 2021 02:17 PM Eastern Daylight Time

Image

GRYT Health and Bristol Myers Squibb Team Up to Launch Diversity in Oncology Initiative

GRYT Health

In light of the health disparities in oncology, GRYT Health (“grit”), an oncology solutions company that was started and run by cancer survivors, and Bristol Myers Squibb, have partnered to launch Diversity in Oncology, a virtual platform available at www.diversityinoncology.com to highlight and raise awareness of the health disparities in oncology facing diverse patients in the U.S. As one example of a racial disparity that exists in oncology, according to the National Institute of Health, “The invasive breast cancer age-adjusted mortality rate for black women age <40 was twice that for white women.” The Diversity in Oncology initiative will co-create a series of live, interactive sessions that bring together a multi-stakeholder audience of local and national organizations, patients and caregivers, healthcare providers, clinical trial teams and principal investigators, schools of public health and others. The goal of the initiative is to have courageous conversations about what’s currently inequitable, so that this cross-stakeholder, cross-cultural initiative can work towards structural changes in clinical trials. By bringing together diverse patients who have experienced inequities, alongside those who run trials, we will highlight current inequities and identify ways to adapt the system. The first of four live sessions will be October 27, 2021, from 4:00 – 5:30pm ET and is titled “Experience of Diverse Patients and Families in Clinical Trials.” It will feature an opening keynote from Wendy Short Bartie, senior vice president, U.S. Oncology at Bristol Myers Squibb, followed by a panel conversation moderated by Megan-Claire Chase, partnership director at GRYT Health and equity advocate. The session will include “break-out” rooms where attendees will be able to interact with the speakers to ask questions and to share their own stories and experiences in cancer clinical trials. “This initiative is about acknowledgment of the real and current issues in cancer clinical trials that need to be fixed,” said Megan-Claire Chase, partnership director at GRYT Health and moderator of the first session on the Diversity in Oncology platform. “This initiative is being developed with the voices of the underrepresented communities living these experiences, so that resources and structural change can be co-designed together.” The panel speakers in the first session will share their own personal experiences - as patients participating in clinical trials, as well as those who chose not to participate in a clinical trial. “When I participated in a clinical trial for breast cancer, the research team never showed any care or concern to my questions,” said Venus Ginés, president and founder, Día de la Mujer Latina® Inc. and speaker on the Oct. 27 session of Diversity in Oncology. “When I shared about the side effects that I was struggling with - they would say ‘I will document it on your file,’ but there was no support or follow-up care. After three months, I left the trial and upon not getting a call-back, I felt it had been a waste of my time.” Venus founded Día de la Mujer Latina® Inc. not only to educate Latinas about breast and cervical cancer, but as a result of her experience. In her work, she teaches promotores/community health workers to be more patient-centered and respectful to their constituents and patients, providing timely responses, resources, and support. Upcoming sessions, all available on the same virtual platform, will focus on topics relevant to bringing awareness to and developing solutions for healthcare inequities, including the experience of diverse physicians, principal investigators in clinical research, improving representation of diversity in clinical trials, and new models of academia and community collaboration in terms of clinical research. The virtual platform will provide resources and access to organizations and individuals advancing health equity, as well as the opportunity to participate in the live, interactive sessions to foster discussion and collaboration. To register for free access to the platform and the series, visit www.DiversityinOncology.com. All sessions will be recorded and also available on demand. Source: Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology (nih.gov) GRYT Health is a digital oncology company that empowers people to be in charge of their own health through education, engagement and support. We offer a community free from judgment that focuses on humanity and the value each person brings. Our mission is to improve quality of life and increase survival for people facing cancer through the relentless focus on patient experience. We put patients first and work with healthcare organizations that do the same. We use the patient voice to enhance drug development and access; and together, we are helping to move healthcare forward. Visit www.grythealth.com or www.solutions.grythealth.com to learn more. Contact Details Lindsay Barnes +1 215-410-9982 Lindsay.Barnes@evokegroup.com Company Website https://www.grythealth.com

October 14, 2021 11:52 AM Eastern Daylight Time

Image

Turning the Lights Out on Fluorescents

Clean Lighting Coalition

A new report released today by the Clean Lighting Coalition highlights the environmental and health risks posed when fluorescent lamps break, especially to vulnerable populations. The report provides concrete steps government, industry, consumers, and others, like childcare providers, can take to accelerate the transition to LED lighting, which is mercury-free, more energy-efficient, more cost-effective, and widely available. To mitigate the risks posed by mercury, the Coalition is calling on the Biden Administration to support the global phase-out of fluorescent lighting by 2025 at the upcoming meeting of the United Nation’s Minamata Convention on Mercury in March 2022. Furthermore, the Coalition notes that phasing out fluorescent lighting aligns with the Administration’s Executive Order on Tackling the Climate Crisis at Home and Abroad issued earlier this year. “Fluorescent lamps have been tolerated for decades because they were considered the most energy-efficient option,” said Alicia Culver, Executive Director of the Responsible Purchasing Network and co-author of the report. “But this is no longer the case: LEDs are twice as energy efficient as fluorescent lamps, last 2-3 times longer, and they don’t contain mercury.” The report details: Health risks to those exposed to mercury, especially populations that are more vulnerable, such as pregnant people and their unborn babies, infants and young children, communities of color, and those living in low-income neighborhoods Health risks to workers exposed to mercury when lamps break during the manufacturing, installation, recycling, and disposal of fluorescent lamps Environmental hazards posed by the release of mercury in fluorescent lighting Benefits of transitioning to LED lighting, now considered the most cost-effective and reliable lighting option in the U.S. marketplace “We know that mercury exposure, especially in early life, can lead to irreversible deficits in verbal skills, reduced attention span and motor control, and lower IQ,” said Michael T. Bender, director of the Mercury Policy Project and one of the report authors. “However, these exposure risks are avoidable by replacing fluorescents with LEDs.” The report recommends steps that government entities, businesses, and consumers can take to accelerate the transition to LEDs. For example, it recommends state and local governments: Adopt and enforce mercury reduction laws to phase out fluorescents. For example, Vermont law bans sales of mercury-containing lamps unless the manufacturer has demonstrated that no comparably performing alternative non-mercury energy-efficient lamp is available at a comparable cost. Update guidance, including on websites, to highlight the hazards of mercury in fluorescent lighting and the advantages of LEDs including reduced risk, better energy efficiency, longer product life, and significant cost savings. Adopt new lighting specifications that prohibit vendors from offering fluorescent lamps, fixtures and ballasts on their state supply contracts. Maryland and Minnesota are already using this approach to eliminate many fluorescent lighting products from their contracts. Develop contracts for environmentally preferable lighting equipment that offer a wide array of LED lighting products at discounted prices. New York State and the City of San Francisco have lighting contracts that feature LEDs. The report also highlights guidelines from the US EPA regarding strict protocols that should be taken when cleaning up broken fluorescent lamps. “There is no safe level of mercury exposure and following US EPA guidelines in cleaning up a broken lamp is not easy,” says Coalition Deputy Director Ana Maria Carreño. " Most people, for example, either don’t know about or find it difficult to follow the proper procedures. Yet, with the tremendous advances in LED technology during the past decade, there’s no reason to continue using fluorescent lighting.” Mercury is highly toxic to humans, which is why the World Health Organization lists it among the top 10 chemicals or groups of chemicals of major public health concern. “The U.S. has been a global leader on many fronts,” said Michael Scholand, LC, of the Coalition and one of a worlds-leading experts on lighting policy and technology. “But when it comes to taking action on fluorescent lighting, the U.S. lags behind some African countries and the European Union, which have already taken steps to phase out mercury-based lighting.” Mercury in Fluorescent Lighting: Unnecessary Health Risks and Actionable Solutions ” was published by the Clean Lighting Coalition in partnership with the Mercury Policy Project and the Responsible Purchasing Network. The report was co-published by the following groups: Vermont Public Interest Research Group, Healthy Babies Bright Futures, Eco-Healthy Child Care, the Children’s Environmental Health Network, Clean Water Action and Ecology Center. The Coalition is encouraging consumers, businesses, and others to sign a pledge to support the global transition to clean and efficient lighting, and to end the manufacture, export and import of mercury-containing fluorescent lighting in the United States by 2025. To learn more, visit https://cleanlightingcoalition.org/advocates-pledge. ____________ For more information about the transition away from mercury-based lighting, visit https://cleanlightingcoalition.org/benefits/ About the Clean Lighting Coalition The Clean Lighting Coalition is a global partnership coordinated by CLASP to capture the health and environmental benefits of eliminating mercury-based lighting. To learn more, visit www.cleanlightingcoalition.org and follow the Coalition on Twitter, Facebook, and LinkedIn. About the Mercury Policy Project Founded in 1998, the Mercury Policy Project promotes policies to eliminate mercury use and reduce mercury exposure. To learn more, visit www.mercurypolicy.org About the Responsible Purchasing Network Responsible Purchasing Network is an international network of buyers dedicated to socially responsible and environmentally sustainable purchasing. To learn more, visit www.responsiblepurchasing.org About Peter Maxson Mr. Maxson is an environmental consultant who has long provided expert advice on mercury to multinational organizations, government agencies, nongovernmental organizations, and others. Contact Details Clean Lighting Coalition Alexia Ross +1 339-222-4311 aross@clasp.ngo Clean Lighting Coalition Ana Maria Carreno +1 202-999-2886 acarreno@clasp.ngo Company Website https://www.cleanlightingcoalition.org

October 14, 2021 09:00 AM Eastern Daylight Time

Bay Area Mental Health adds Ketamine Assisted Psychotherapy to its Services as the Psychedelic Renaissance Booms

Bay Area Mental Health

California based mental health clinic, Bay Area Mental Health (BAMH) is officially announcing that they have added Ketamine Assisted Psychotherapy (KAP) to their offerings in order to better serve the needs of Silicon Valley and surrounding areas. Bay Area Mental Health is the first mental health clinic in Silicon Valley’s South Bay to offer Ketamine Assisted Psychotherapy, and is laying the foundation to provide additional psychedelic therapies as soon as they become available. For now, the only legal form of psychedelic-assisted psychotherapy uses ketamine, which is not a traditional psychedelic, but has mind-altering properties that have been found to relieve depression, anxiety and PTSD when used appropriately and under supervision of licensed professionals. The rates of depression, anxiety, PTSD and suicidality is continuing to climb. BAMH founder Linnea Butler states, “we have a mental health epidemic in the United States. More urgently than ever, we need new approaches to complex mental health problems that are not treated by talk therapy alone. Ketamine is safe, legal, and accessible and shows many of the same benefits as the more traditional, but largely inaccessible, psychedelic medicines. We have seen as much as a 70% reduction in symptoms over a 6 week course of ketamine assisted psychotherapy treatment and in one case we witnessed a near complete remission of trauma, depression and anxiety.” Butler specializes in treating complex trauma and mood disorders, and currently oversees Ketamine Assisted Psychotherapy at the clinic. Butler has been accepted into the MAPS MDMA Assisted Therapy training program and is on track to complete her certificate by the end of 2021. The results of a successful phase-three drug trial of MDMA Assisted Therapy were reported in May that showed that 67% of patients with PTSD were cured. MDMA will likely be available to clinics in the next 2 years, pending FDA approval. Butler stated, “it is critical that we work within the legally allowed and approved medicines and procedures, otherwise it becomes the wild west; emotional and physical safety is paramount”. Clients are evaluated psychologically and medically to ensure that they are appropriate for this treatment. This work is overseen by founder and licensed therapist, Linnea Butler, and integrative psychiatrist Dr. Sidney Edsall. A ketamine assisted psychotherapy session is typically 3 hours long and clients are attended to throughout the session. Sessions begin with preparation and setting the intention for the psychedelic experience, followed by self-administration of doctor-prescribed medicine, and finally processing and integration of the experience. The patient wears an eye mask and listens to specifically curated music to help guide the experience. Butler’s scientific background as a molecular biologist and geneticist has driven her to look deeply at the intersection between science and psychology. Butler explains, “we are on the cutting edge of mental health care, where neuroscience meets experiential treatment, spirituality and depth psychology. Talk therapy is no longer adequate to address the increasingly complex nature of mental health problems, where people often are struggling with more than one diagnosis. The need for a new paradigm is urgent.” Butler will be speaking about Ketamine Assisted Psychotherapy at an online event next month: “ Ketamine: The Science and Spirit of Psychedelic Healing “ About Bay Area Mental Health BAMH was founded in 2014 to treat people with complex mental health issues, including Trauma and complex PTSD, that often necessitate multiple different approaches and healing modalities. BAMH is dedicated to helping people with difficult problems using cutting edge approaches and collaborative care. Linnea Butler is a licensed marriage and family therapist and the founder of Bay Area Mental Health, Linnea specializes in treating complex trauma, has been featured on the Trauma Therapist Podcast, and was an Adjunct Professor at Sofia University and guest lecturer at Santa Clara University. Linnea received her M.S. degree in Genetics and Molecular Biology under the direction of Nobel Laureate Dr. Mario Cappechi, and her M.A. degree in Counseling Psychology from Institute of Transpersonal Psychology. Dr. Sidney Edsall is a board-certified psychiatrist and completed her residency at Stanford in integrative medicine. She integrates Western medical practices with Traditional Chinese Medicine by cultivating treatment plans using Western medicine terminology infused with Buddhist and Daoist philosophy. She also spent 4 years living and working abroad in Germany and Italy caring for active duty U.S. Army soldiers on U.S. military bases. For more information about mental health therapy services provided by BAMH, please visit the company website at: www.bayareamentalhealth.com Contact Details Bay Area Mental Health Linnea Butler, LMFT +1 669-240-5505 linnea@bayareamh.com Company Website https://www.bayareamh.com

October 14, 2021 09:00 AM Eastern Daylight Time

Video Image

Cepheid recibe el marcado CE para Xpert Xpress CoV-2/Flu/RSV plus

Cepheid

Cepheid anunció hoy que ha recibido el marcado CE para el ensayo Xpert Xpress CoV-2/Flu/RSV plus, una prueba de diagnóstico molecular rápido para la detección cualitativa de los virus que causan la COVID-19, la gripe A, la gripe B y el virus respiratorio sincitial (RSV) en una muestra única de paciente. La nueva versión plus de la prueba proporciona una tercera diana génica para la detección del virus SARS-CoV-2 con el fin de afrontar el problema de futuras mutaciones del virus. Xpert Xpress CoV-2/Flu/RSV plus está diseñada para utilizarse en cualquiera de los más de 35 000 sistemas GeneXpert ® de Cepheid existentes en todo el mundo y proporcionar resultados en aproximadamente 36 minutos. Durante la pandemia, en el mundo se han documentado diversas variantes del virus que causa la COVID-19. Los virus cambian constantemente mediante mutación, y con el tiempo se espera que aparezcan nuevas variantes. La adición de una 3ª diana génica a la versión plus de la prueba CoV-2/Flu/RSV de Cepheid proporciona una cobertura más amplia para mitigar los posibles efectos de las futuras variaciones genéticas del virus. «En esta temporada de enfermedades respiratorias, el personal sanitario puede enfrentarse a diversas infecciones víricas que cursan con síntomas similares a los de la COVID-19, como la gripe A y B, y el virus respiratorio sincitial. Disponer de una prueba rápida y precisa, diseñada para detectar las variantes actuales y futuras de los virus que causan la COVID-19 y la gripe será cada vez más importante», afirmó el Dr. David Persing, MD, Ph.D., Director médico y tecnológico de Cepheid. «La posibilidad de recoger una muestra y realizar una única prueba multiplex de alta sensibilidad que detecte y distinga los cuatro virus proporcionará resultados prácticos para tomar mejores decisiones en primera línea en nuestros sistemas sanitarios». Se espera que esta semana se empiece a enviar ya la prueba Xpert Xpress CoV-2/Flu/RSV plus a los países que acepten productos con marcado CE. Visite https://www.cepheid.com/en para obtener más información, vídeos y prospectos. Para consultas a Cepheid, relacionadas con los medios de comunicación, contacte con: Darwa Peterson darwa.peterson@cepheid.com Acerca de Cepheid Cepheid, con sede en Sunnyvale, Calif., Cepheid es una empresa líder en diagnóstico molecular. Cepheid tiene el compromiso de mejorar la atención sanitaria mediante el desarrollo, la fabricación y la comercialización de sistemas y pruebas moleculares precisos y fáciles de utilizar. Con la automatización de procesos manuales sumamente complejos y laboriosos, las soluciones de la empresa ofrecen a las instituciones de cualquier tamaño una mejor manera de realizar pruebas de diagnóstico molecular sofisticadas para la detección de microorganismos y enfermedades genéticas. Aprovechando sus extensas capacidades en biología molecular, el trabajo de la empresa se centra en aquellas aplicaciones en las que más se necesitan resultados precisos, rápidos y fiables, como el control de las enfermedades infecciosas y el cáncer. Para obtener más información, visite http://www.cepheid.com. Contact Details kdm communcations Sarah Khan +44 1480 405333 sarahk@kdm-communications.com Company Website https://www.cepheid.com/en

October 14, 2021 08:10 AM Eastern Daylight Time

Image

KOAN CORDIALS ARE NOW AVAILABLE FOR DELIVERY THROUGHOUT CALIFORNIA

Resonate Blends, Inc

Koan, a Resonate Blends brand, is leading a new area of plant-based wellness with the direct-to-consumer launch of the world’s first cannabis cordials - non-alcoholic, single-dose, plant-derived liquids designed to help mindful consumers to find inspiration, restore balance, and improve the quality of their lives. By combining the wisdom of traditional, holistic wellness practices with cutting-edge science and technology, Koan has developed a brand-new way to harness the wide-ranging benefits of cannabis, utilizing various ratios of THC and CBD, along with botanical terpenes, adaptogens, and other plant extracts to deliver precise and consistent life-enhancing experiences. The six cordials - Calm, Balance, Play, Create, Delight, and Wonder – have the fast on-set of a tincture, the long duration of an edible, and the ease and social benefits of a beverage all in one single-dose bottle. Calm, for example, has a large concentration of CBD with low levels of THC ensuring a profoundly calming experience without getting you high. The low level of THC amplifies the benefits of natural plant extracts including Linalool—known to help treat anxiety, depression, and insomnia—Beta-Caryophyllene, an anti-inflammatory, and Limonene—a naturally-derived anti-depressive—to help ease stress and return to a comfortable and functional mind/body state. On the other extreme is Koan's Wonder formulation carefully crafted to support consumers in every way when their goal is to ponder the infinite. Wonder has higher levels of THC with low levels to CBD designed to help refine the powerful experience. Koan's other blends of Cordials enhance creativity, bring a feeling of enchantment, or unleash a feeling of energy, joy, and more. The full range of products is designed to help those using cannabis in an intentional way to find what they are looking for with precision, consistency, and refinement. “At Koan we’re mastering the art of experience. It’s more than science, it’s our passion - refining, amplifying, and calibrating cannabis so you can always find what you are looking for. We are deeply enmeshed in the science, we have two patents pending supporting our formulations, processes, and bioavailability to ensure that consumers get exactly what they expect, every time, from our products,” said Geoff Selzer, CEO and Founder. “We are delighted to partner with Grassdoor for our direct to home delivery ensuring that all of our customers can get our products whenever they choose in the most convenient, safe, discrete, and reliable fashion possible.” Koan is committed to demystifying cannabis and harnessing its impactful ingredients to create products that support intentional and mindful use as a core part of daily wellness—physical, spiritual, and most importantly, emotional. Through precision crafting, Koan invites a general sense of well-being, lean-in awareness and presence rather than the “check-out high” normally associated with most cannabis-based products. The single-dose cordials are artfully designed to be both portable and discrete, with fast-acting ingredients that allow a quick onset for a long-lasting experience of up to four hours. The delightful citrus and botanical notes of the cordials can be enjoyed directly out of the bottle or poured into any beverage or one of Koan’s signature cannabis cocktail recipes. Koan Cordials are now available for purchase directly at https://koan.life. Koan provides the option to order individual cordial three packs, or in themed bundles such as the Serenity Bundle, Engage Bundle, or the Experience Bundle. Koan has proudly partnered with Grassdoor, the premier direct-to-consumer e-commerce solution for cannabis brands in California, to allow consumers to shop Koan’s portfolio of Cordials with same-day delivery across Southern California (including Los Angeles and San Diego) and Northern California (including San Francisco, San Jose, and Oakland). Grassdoor is one of the largest end-to-end delivery solutions in cannabis, providing same-day delivery to 75% of the population of California. ABOUT RESONATE BLENDS, INC. Resonate Blends, Inc. (OTCQB:KOAN) develops Koan Cordials, meticulously formulated blends of THC, CBD, Terpenes, and Botanicals that provide a refined cannabis experience. Unlike strain-based or full-spectrum products, Koan Cordials are scientifically crafted to highlight specific cannabis characteristics, with predictable experiences and intensity allowing people to tap into specific feelings in a new, better way. ABOUT GRASSDOOR Grassdoor is the premier delivery marketplace and direct-to-consumer ecommerce platform in cannabis, providing customers same-day delivery of top brands in 45 minutes or less throughout California, including Los Angeles, Orange County, San Diego, Ventura, San Francisco, San Jose, Oakland, and more. In addition to being the fastest licensed delivery service in the state, Grassdoor aims to be the safest, friendliest, and most reliable cannabis delivery solution worldwide. This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of forward-looking statements include, among others, statements we make regarding guidance relating to net income; anticipated customer onboardings; and expected operating results, such as revenue growth and earnings. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set out in the Company's SEC filings. These risks and uncertainties could cause the Company's actual results to differ materially from those indicated in the forward-looking statements. Contact Details BPCM Katie Bell +1 323-655-5541 koancordials@bpcm.com Company Website https://www.resonateblends.com

October 13, 2021 08:03 AM Pacific Daylight Time

Holland & Barrett backs Floe Oral Care to tackle gum disease via salivary biomarkers

Floe Oral Care

Floe Oral Care, the oral healthcare business dedicated to improving oral and systemic health by means of a direct-to-consumer subscription, has secured £350k from a group of high profile investors including Holland & Barrett, Lord Mervyn Davies, Tim Farazmand, Professor John Deanfield CBE, Sir Nigel Rudd, and Julio Bruno. Existing shareholders Stephen Welton, Dr. Jose Navarro, and Charles Southey are also following on. Founded by Anglo-Spanish duo Will Welton and Javier Navarro, Floe is an online subscription service on a mission to address the UK’s ‘dental care timebomb’ by building a preventative routine for consumers and providing vital insights into undetected gum disease. Will Welton, Co-founder at Floe Oral Care said: “If your mouth is the gateway to your body, then protecting it requires not only using the right products but also visibility of what condition your gums are in. The impact of gum disease is significant, and the prevalence of periodontitis has barely changed over the last 20 years. Our mission is to build a service that both tracks and improves oral and systemic health. We want to encourage a pro-active relationship with dental care by capturing and contextualising oral health data, and are thrilled to be bringing on board a fantastic group of investors from business and healthcare as well as an excellent and highly relevant corporate partner. This is a great platform for the next stage of our development” Periodontitis is now the sixth most prevalent disease in the world, and according to research led by The Economist Intelligence Unit (IEU), costs the UK £6.4bn a year in treatment. Nearly half the adults in the UK have some form of periodontal disease, which has increasingly been shown to raise the risk of serious health conditions including cardiovascular disease and diabetes. Its awareness has remained low however amongst the general public and other health professionals - it’s often referred to as a silent killer - with the study showing that three out of four adults with periodontitis do not know they have the condition at all. Tamara Rajah MBE, Chief Business & Science Officer, Holland and Barrett: “H&B are committed to making health and wellness a way of life for everyone, and to supporting early-stage innovation in wellness as part of our strategy. Recognising that effective oral health management can disproportionately impact an individual’s overall health and wellness, coupled with our interest about the potential of diagnostics, makes Floe very exciting for us. We look forward to working with Will, Javier and the team at Floe to optimise the way we manage our oral health and improve lives.” Floe is building a data driven approach, designed to cast light on untreated periodontitis and put the right measures in place to improve it. The service will track gum health via proprietary at home saliva testing whilst delivering essential products to support your oral health. Floe launched their core dental kit in August 2020, delivering their own unique toothpaste formulations (Dusk and Dawn), an ultra-soft toothbrush, and charcoal dental floss, delivered every three months to improve preventative habits in a more sustainable way. The products are all built with the environment in mind, including a free-returns service collecting used products for specialist recycling when subscribers' new boxes arrive. Julio Bruno, CEO of Time Out Group plc, will be joining the board as a Non-Executive Director whilst Stephen Welton, founder and Executive Chairman of BGF, the UK’s largest growth capital investor, will remain as the Chairman. Professor John Deanfield CBE joins Floe as Chief Medical Officer, to put together a world leading Advisory Board to inform the strategy of the saliva testing and future healthcare products. Professor Deanfield is one of the leading cardiologists in the UK and has published several papers on the linkage between oral and systemic health. Professor John Deanfield CBE commented: “We now understand the big impact oral health can have on important diseases in the rest of the body. This underpins a new opportunity to benefit from a change in approach to oral health – I am excited to be joining Floe to help address this.” About Floe Oral Care Floe Oral Care is a subscription service providing core dental products/ services on a quarterly basis with a closed loop recycling process to ensure that plastic doesn’t end up in the ocean. It was co-founded by William Welton and Javier Navarro to deliver technology enabled dental healthcare solutions whilst protecting the planet’s environment. Javier comes from a family of dentists and spent the first part of his career in banking. Will’s background is in consumer goods with commercial roles within the drinks industry and e-commerce. For careers please get in touch via CV and covering letter to hello@getfloe.com. About Holland & Barrett Holland & Barrett is the UK’s leading wellness retailer* and one of the largest in Europe. We make health and wellness and way of life for everyone, with a leading range of own brand, innovative vitamins, supplements, specialist food, sports nutrition and ethical beauty brands. Established in 1870, Holland & Barrett has been trusted for wellness for over 150 years and is owned by the Letter One Retail Group (L1 Retail). Holland & Barrett has a retail presence of more than 1000 stores across 16 countries worldwide, including over 800 in the UK and Ireland**, as well as a rapidly expanding e-commerce business. Holland & Barrett’s colleagues are “qualified to advise” with in depth training in nutrition and supplements to give accessible personalised advice to customers on their individual needs. *Kantar Brand Tracking – health and wellness retailers March 2021 ** up to 30 September 2020. Contact Details Floe Oral Care Bilal Mahmood +44 7714 007257 bilal@getfloe.com Company Website https://getfloe.com/

October 13, 2021 08:00 AM Eastern Daylight Time

Image

1 ... 229 230 231 232 233 ... 281